These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 25873172)
1. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Zhu EF; Gai SA; Opel CF; Kwan BH; Surana R; Mihm MC; Kauke MJ; Moynihan KD; Angelini A; Williams RT; Stephan MT; Kim JS; Yaffe MB; Irvine DJ; Weiner LM; Dranoff G; Wittrup KD Cancer Cell; 2015 Apr; 27(4):489-501. PubMed ID: 25873172 [TBL] [Abstract][Full Text] [Related]
2. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515 [TBL] [Abstract][Full Text] [Related]
3. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570 [TBL] [Abstract][Full Text] [Related]
4. Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy. Moskalenko M; Pan M; Fu Y; de Moll EH; Hashimoto D; Mortha A; Leboeuf M; Jayaraman P; Bernardo S; Sikora AG; Wolchok J; Bhardwaj N; Merad M; Saenger Y Cancer Immunol Res; 2015 Mar; 3(3):296-304. PubMed ID: 25600438 [TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196 [TBL] [Abstract][Full Text] [Related]
6. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies. Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037 [TBL] [Abstract][Full Text] [Related]
7. IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. Davies E; Reid S; Medina MF; Lichty B; Ashkar AA J Leukoc Biol; 2010 Sep; 88(3):529-36. PubMed ID: 20538758 [TBL] [Abstract][Full Text] [Related]
8. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. Jin GH; Hirano T; Murakami M Int Immunol; 2008 Jun; 20(6):783-9. PubMed ID: 18448458 [TBL] [Abstract][Full Text] [Related]
9. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy. Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B Front Immunol; 2018; 9():2905. PubMed ID: 30619269 [TBL] [Abstract][Full Text] [Related]
10. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238 [TBL] [Abstract][Full Text] [Related]
11. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Guo Z; Wang H; Meng F; Li J; Zhang S J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551 [TBL] [Abstract][Full Text] [Related]
12. Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma. Han KH; Kim KW; Yan JJ; Lee JG; Lee EM; Han M; Cho EJ; Kang SS; Lim HJ; Koo TY; Ahn C; Yang J BMC Urol; 2016 Jan; 16():2. PubMed ID: 26772545 [TBL] [Abstract][Full Text] [Related]
13. IL-15: targeting CD8+ T cells for immunotherapy. Diab A; Cohen AD; Alpdogan O; Perales MA Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381 [TBL] [Abstract][Full Text] [Related]
14. Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation. Jing H; Hettich M; Gaedicke S; Firat E; Bartholomä M; Niedermann G J Immunother Cancer; 2019 Feb; 7(1):55. PubMed ID: 30808414 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Slos P; De Meyer M; Leroy P; Rousseau C; Acres B Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452 [TBL] [Abstract][Full Text] [Related]
16. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295 [TBL] [Abstract][Full Text] [Related]
17. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents. Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033 [TBL] [Abstract][Full Text] [Related]
19. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer. Zhang S; Zhao J; Bai X; Handley M; Shan F Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444 [TBL] [Abstract][Full Text] [Related]
20. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]